ArticleBMC cancer2025
Mutation patterns and prognostic potentiality of homologous recombination repair genes in gliomas.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fumarate hydratase-deficient renal cell carcinoma: high intratumoral and peritumoral CD4-positive T cell infiltration density and high PD-L1 expression.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are primary malignant brain tumors with poor prognosis. Conventional therapies have achieved limited improvements, and there is an urgent need for new treatments. Homologous recombination repair (HRR) defects are observed in many types of cancer and confer increased sensitivity to platinum-based chemotherapies and poly-ADP ribose polymerase (PARP) inhibitors. To our knowledge, HRR mutations in gliomas have not been extensively reported. To this end, we analyzed alterations in 39 HRR related genes and divided patients with glioma into different groups according to HRR LOF mutation status. We then analyzed the differences in genetic mutation landscape, TMB, CNV burden, prognosis, and immune-related features between the HRR-LOF group and the NonHRR-LOF group. The results demonstrated that compared to the non-HRR-LOF group, the HRR-LOF group exhibited a higher mutation frequency of IDH1, increased TMB, and poor prognosis in IDH-mutant patients. In summary, gliomas patients with HRR LOF have relatively more unstable genomes and might benefit from the combination and sequential use of PARP inhibitors, radiotherapy, and immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.